QQQ   297.14 (+1.30%)
AAPL   146.90 (+2.04%)
MSFT   248.60 (+0.24%)
META   152.56 (+3.57%)
GOOGL   99.89 (+2.43%)
AMZN   102.56 (+3.37%)
TSLA   179.06 (+11.72%)
NVDA   205.01 (+3.53%)
NIO   12.84 (+5.51%)
BABA   118.82 (-1.45%)
AMD   76.22 (+1.41%)
T   19.94 (-0.30%)
MU   63.85 (+1.67%)
F   13.31 (+3.02%)
CGC   2.90 (+5.07%)
GE   83.68 (+3.13%)
DIS   110.42 (+0.66%)
AMC   5.52 (+4.55%)
PFE   44.15 (-0.23%)
PYPL   82.11 (+1.61%)
NFLX   362.65 (-0.61%)
QQQ   297.14 (+1.30%)
AAPL   146.90 (+2.04%)
MSFT   248.60 (+0.24%)
META   152.56 (+3.57%)
GOOGL   99.89 (+2.43%)
AMZN   102.56 (+3.37%)
TSLA   179.06 (+11.72%)
NVDA   205.01 (+3.53%)
NIO   12.84 (+5.51%)
BABA   118.82 (-1.45%)
AMD   76.22 (+1.41%)
T   19.94 (-0.30%)
MU   63.85 (+1.67%)
F   13.31 (+3.02%)
CGC   2.90 (+5.07%)
GE   83.68 (+3.13%)
DIS   110.42 (+0.66%)
AMC   5.52 (+4.55%)
PFE   44.15 (-0.23%)
PYPL   82.11 (+1.61%)
NFLX   362.65 (-0.61%)
QQQ   297.14 (+1.30%)
AAPL   146.90 (+2.04%)
MSFT   248.60 (+0.24%)
META   152.56 (+3.57%)
GOOGL   99.89 (+2.43%)
AMZN   102.56 (+3.37%)
TSLA   179.06 (+11.72%)
NVDA   205.01 (+3.53%)
NIO   12.84 (+5.51%)
BABA   118.82 (-1.45%)
AMD   76.22 (+1.41%)
T   19.94 (-0.30%)
MU   63.85 (+1.67%)
F   13.31 (+3.02%)
CGC   2.90 (+5.07%)
GE   83.68 (+3.13%)
DIS   110.42 (+0.66%)
AMC   5.52 (+4.55%)
PFE   44.15 (-0.23%)
PYPL   82.11 (+1.61%)
NFLX   362.65 (-0.61%)
QQQ   297.14 (+1.30%)
AAPL   146.90 (+2.04%)
MSFT   248.60 (+0.24%)
META   152.56 (+3.57%)
GOOGL   99.89 (+2.43%)
AMZN   102.56 (+3.37%)
TSLA   179.06 (+11.72%)
NVDA   205.01 (+3.53%)
NIO   12.84 (+5.51%)
BABA   118.82 (-1.45%)
AMD   76.22 (+1.41%)
T   19.94 (-0.30%)
MU   63.85 (+1.67%)
F   13.31 (+3.02%)
CGC   2.90 (+5.07%)
GE   83.68 (+3.13%)
DIS   110.42 (+0.66%)
AMC   5.52 (+4.55%)
PFE   44.15 (-0.23%)
PYPL   82.11 (+1.61%)
NFLX   362.65 (-0.61%)
NASDAQ:EOLS

Evolus - EOLS Stock Forecast, Price & News

$10.08
-0.42 (-4.00%)
(As of 01/27/2023 03:10 PM ET)
Add
Compare
Today's Range
$9.90
$10.46
50-Day Range
$6.52
$11.05
52-Week Range
$6.51
$14.34
Volume
444,328 shs
Average Volume
497,746 shs
Market Capitalization
$566.97 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$16.67

Evolus MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.83 Rating Score
Upside/​Downside
66.5% Upside
$16.67 Price Target
Short Interest
Bearish
6.99% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.27
Upright™ Environmental Score
News Sentiment
0.56mentions of Evolus in the last 14 days
Based on 13 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($1.12) to ($0.44) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.99 out of 5 stars

Medical Sector

684th out of 1,055 stocks

Pharmaceutical Preparations Industry

346th out of 519 stocks


EOLS stock logo

About Evolus (NASDAQ:EOLS) Stock

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November 2012 and is headquartered in Newport Beach, CA.

Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Stock News Headlines

Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Evolus (NASDAQ:EOLS) Trading Up 3.9% on Analyst Upgrade
Why Evolus Shares Jumped This Week
Evolus (NASDAQ:EOLS) Price Target Raised to $20.00
Evolus (NASDAQ:EOLS) Shares Gap Up to $8.46
Is This The End of Capitalism?
EXPOSED: The establishment plot to disenfranchise and impoverish millions of Americans…
Evolus (NASDAQ:EOLS) Given New $17.00 Price Target at Mizuho
Evolus, Inc.'s (NASDAQ:EOLS) Shift From Loss To Profit
Evolus Third Quarter 2022 Earnings: Revenues Disappoint
This Options Play Could Turn That Frown Upside Down - RealMoney
See More Headlines
Receive EOLS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Evolus and its competitors with MarketBeat's FREE daily newsletter.

EOLS Company Calendar

Last Earnings
11/08/2022
Today
1/27/2023
Next Earnings (Estimated)
3/02/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:EOLS
Fax
N/A
Employees
167
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$16.67
High Stock Price Forecast
$20.00
Low Stock Price Forecast
$10.00
Forecasted Upside/Downside
+65.3%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.83
Research Coverage
6 Analysts

Profitability

Net Income
$-46,810,000.00
Pretax Margin
-56.85%

Debt

Sales & Book Value

Annual Sales
$99.67 million
Book Value
$1.47 per share

Miscellaneous

Free Float
52,141,000
Market Cap
$566.97 million
Optionable
Optionable
Beta
1.83

Key Executives

  • David MoatazediDavid Moatazedi
    President, Chief Executive Officer & Director
  • Sandra Beaver
    Chief Financial Officer
  • Rui AvelarRui Avelar
    Chief Medical Officer, Head-Research & Development
  • Dan Stewart
    Vice President & General Manager
  • Christos Monovoukas
    Senior Vice President-Corporate Development













EOLS Stock - Frequently Asked Questions

Should I buy or sell Evolus stock right now?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Evolus in the last twelve months. There are currently 1 hold rating and 5 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" EOLS shares.
View EOLS analyst ratings
or view top-rated stocks.

What is Evolus' stock price forecast for 2023?

6 equities research analysts have issued 12-month target prices for Evolus' shares. Their EOLS share price forecasts range from $10.00 to $20.00. On average, they anticipate the company's share price to reach $16.67 in the next year. This suggests a possible upside of 58.7% from the stock's current price.
View analysts price targets for EOLS
or view top-rated stocks among Wall Street analysts.

How have EOLS shares performed in 2023?

Evolus' stock was trading at $7.51 at the start of the year. Since then, EOLS stock has increased by 39.8% and is now trading at $10.50.
View the best growth stocks for 2023 here
.

When is Evolus' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, March 2nd 2023.
View our EOLS earnings forecast
.

How were Evolus' earnings last quarter?

Evolus, Inc. (NASDAQ:EOLS) released its earnings results on Tuesday, November, 8th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.31) by $0.05. The company earned $33.90 million during the quarter, compared to analysts' expectations of $36.94 million. Evolus had a negative net margin of 56.88% and a negative trailing twelve-month return on equity of 141.07%.

What guidance has Evolus issued on next quarter's earnings?

Evolus issued an update on its FY 2022 earnings guidance on Friday, January, 27th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $148.60 million-$148.60 million, compared to the consensus revenue estimate of $148.30 million.

What is David Moatazedi's approval rating as Evolus' CEO?

1 employees have rated Evolus Chief Executive Officer David Moatazedi on Glassdoor.com. David Moatazedi has an approval rating of 100% among the company's employees. This puts David Moatazedi in the top 10% of approval ratings compared to other CEOs of publicly-traded companies.

What other stocks do shareholders of Evolus own?
When did Evolus IPO?

(EOLS) raised $65 million in an IPO on Thursday, February 8th 2018. The company issued 5,000,000 shares at $12.00-$14.00 per share. Cantor and Mizuho Securities acted as the underwriters for the IPO and SunTrust Robinson Humphrey and JMP Securities were co-managers.

What is Evolus' stock symbol?

Evolus trades on the NASDAQ under the ticker symbol "EOLS."

Who are Evolus' major shareholders?

Evolus' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Strs Ohio (0.02%). Insiders that own company stock include Alphaeon 1 Llc, Crystal Muilenburg, David Moatazedi, David N Gill, Lauren P Silvernail, Medytox Inc, Robert Hayman, Rui Avelar and Vikram Malik.
View institutional ownership trends
.

How do I buy shares of Evolus?

Shares of EOLS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Evolus' stock price today?

One share of EOLS stock can currently be purchased for approximately $10.50.

How much money does Evolus make?

Evolus (NASDAQ:EOLS) has a market capitalization of $590.63 million and generates $99.67 million in revenue each year. The company earns $-46,810,000.00 in net income (profit) each year or ($1.42) on an earnings per share basis.

How many employees does Evolus have?

The company employs 167 workers across the globe.

How can I contact Evolus?

Evolus' mailing address is 520 Newport Center Dr. Suite 1200, Newport Beach CA, 92660. The official website for the company is www.evolus.com. The company can be reached via phone at (949) 284-4555 or via email at ir@evolus.com.

This page (NASDAQ:EOLS) was last updated on 1/27/2023 by MarketBeat.com Staff